Emmanuella Adenokun

Emmanuella Adenokun

Auto-generated profile, based on publicly available information

Emmanuella Adenokun

University of Lagos, Faculty of Pharmacy, Department of Pharmaceutics and Pharmaceutical Technology, Lagos, Nigeria

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 April 2022 in Turkish Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
MARGARET OKONAWAN ILOMUANYAMARGARET OKONAWAN ILOMUANYA
MARGARET OKONAWAN ILOMUANYA
NENkechi V Enwuru
Nkechi V Enwuru
EAEmmanuella Adenokun
Emmanuella Adenokun
AFAbigail Fatunmbi
Abigail Fatunmbi
AAAdebowale Adeluola
Adebowale Adeluola
CICecilia I Igwilo
Cecilia I Igwilo
Multi-drug resistant bacteria have been implicated in various debilitating infections that have led to life loss. This study developed an approach to tackle multidrug resistant Acinetobacter baumannii infection in a chronic wound model through A. baumannii phage encapsulation with resuspension in hydrogel. Two isolates of A. baumannii-specific lytic phases ɸAB140 and ɸAB150 alone, in combination (cocktail) encapsulated within a chitosan (CS) microparticle was suspended in CS hydrogel and evaluated for their therapeutic efficacy to ensure bacterial clearance in A. baumannii induced diabetic wound infection. Microencapsulation of the phage was carried out using ionic gelation techniques Biological characterization via cell cytoxicity, in vivo wound healing, histology and histomorphometry was carried out. Two characterized A. baumannii phages (ɸAB140 and ɸAB150), specific to twenty A. baumannii isolates, were isolated. The encapsulated CS microparticle hydrogel exhibited a pH of 5.77 ± 0.05. The wound size reduction was most pronounced in formulation C2, which showed statistically significant wound seize reduction on days 4 and 7, 56.79 ± 2.02% and 62.15 ± 5.11%, respectively. The optimized concentration of C2 was not toxic to the cells as it adequately supported cell growth with a proliferation rate of 215 ± 7.89% compared to control (107.32 ± 4.55%). Microparticle carrier technology was used to show the lytic activity against multi drug-resistant A. baumannii. In vivo results showed significant wound size reduction that was most pronounced in formulation C2 on day 4.